Study backs use of metformin as first-line therapy for diabetes

03/14/2011 | WebMD

A meta-analysis found that among several classes of drugs for type 2 diabetes, metformin appears to have the best risk-benefit profile when given as monotherapy or as combination treatment to control patients' blood glucose levels. "Although the long-term benefits and harms of diabetes medications remains unclear, the evidence supports the use of metformin as a first-line agent," researchers wrote in the Annals of Internal Medicine.

View Full Article in:

WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC